Haug Partners’ Life Sciences Litigation team is recognized nationwide for its excellence in representing global pharmaceutical, biotechnology, and medical device companies, including in complex commercial matters and actions brought under the Hatch Waxman Act. Our team is comprised of experienced trial attorneys, scientific advisors, and registered patent attorneys, many of whom have advanced degrees in specialized technical fields such as molecular and cellular biology, biochemistry, organic chemistry, and pharmacology, coupled with extensive hands-on experience in the life sciences industry. Our litigators are able to draw on their legal and scientific expertise to explain complicated legal and technical concepts to judges and juries.
Life Sciences Litigation has been the lifeblood of the firm since its founding in 1997. Haug Partners’ unique, cross-functional biotechnology and biopharmaceutical litigation, patent litigation, and FDA practices also enable our Life Sciences Litigation team to provide seamless, interdisciplinary counseling and representation across all phases of a litigation lifecycle, from pre-suit strategy and patent analysis to appeals before the Court of Appeals for the Federal Circuit. Haug Partners regularly appears before state and federal courts across the country, as well as the Patent Trial and Appeal Board. Because many life sciences disputes are global in scope, Haug Partners is adept at developing strategies that cross borders.
Haug Partners has appeared as lead trial counsel in about two hundred Hatch-Waxman litigations in its twenty-three year history, involving more than sixty different pharmaceutical products. The Life Sciences Litigation team’s achievements include successfully representing or obtaining favorable settlements on behalf of global pharmaceutical companies for drug products such as:
